Any current/future capex/capital investment/strategic investment?

The company is exploring an increase in capacity for Lockheed Martin orders after fulfilling the initial supply by March 2024; more clarity expected in the next quarter. CFS Europe plant is contemplating alternative uses, including manufacturing another HQ downstream product by a different chemistry, with a course of action to be finalized by March 2024. The Chinese subsidiary plant remains closed but is planned to be restarted in the second half of FY25, focusing on manufacturing Heliotropin (catechol downstream). No explicit mention of new major capex projects; emphasis is on optimizing exis

Future growth expectations in sales/revenue/volumes?

Vanillin sales provide significant growth potential as current sales are insignificant; expected scale-up to contribute substantially to revenue (Page 9). Vanillin utilization expected to reach 40-50% in FY25, with potential for higher utilization if market conditions improve (Pages 14, 7). New product introductions underway with aggressive rollout planned in FY25; new products expected to contribute about 10% of business next year (Page 13). Blends business in North America, Mexico, and Brazil growing well with sustainable margins; expected to maintain profitability and grow ~25% in FY25 (Pag

Future growth expectations in earnings/operating earnings/profits/EPS?

Vanillin production scale-up is expected to contribute significantly to future growth, with plant utilization targeted at 40-50% in FY25, depending on market conditions. New products, particularly in blends and downstream segments, are anticipated to account for at least 10% of business by next financial year, driving incremental revenue. Growth of blends business in North America, Mexico, and Brazil is robust and expected to sustain with a targeted 25% growth in FY25. Pricing pressure from Chinese predatory pricing is expected to ease in next 2-3 quarters as Chinese demand picks up due

Current/ Expected Orderbook/ Pending Orders?

Current order book for Lockheed Martin includes the first battery supply order, expected to be fulfilled by end of March 2024. Further discussions on increasing capacity for Lockheed Martin are ongoing, with more clarity expected next quarter. Vanillin orders: substantial quantities already dispatched in Q4, with sales expected to scale up to 130-150 tons per month starting February. Vanillin inventory held is valued roughly at Rs. 70 crores. Customers in aroma business are cautious about entering long-term contracts due to market volatility; mainly quarterly or half-yearly contracts are favor

Camlin FineQ3 FY24Chemicals & Petrochemicals

Camlin Fine Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹91Market Cap: ₹1.9K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

Vanillin sales provide significant growth potential as current sales are insignificant; expected scale-up to contribute substantially to revenue (Page 9).
Vanillin utilization expected to reach 40-50% in FY25, with potential for higher utilization if market conditions improve (Pages 14, 7).
New product introductions underway with aggressive rollout planned in FY25; new products expected to contribute about 10% of business next year (Page 13).
Blends business in North America, Mexico, and Brazil growing well with sustainable margins; expected to maintain profitability and grow ~25% in FY25 (Pages 8, 9).
Indian facility running at ~90% utilization; growth expected from volume scale-up rather than pricing alone (Page 9).
Price pressures from Chinese dumping expected to ease in 2-3 quarters, potentially aiding volume and revenue growth (Pages 9, 11).
European plant revenue anticipated to rise post-Q4 FY24 with ongoing cost control measures (Pages 7, 14).

Margin guidance

Category 3

Vanillin production scale-up is expected to contribute significantly to future growth, with plant utilization targeted at 40-50% in FY25, depending on market conditions.
New products, particularly in blends and downstream segments, are anticipated to account for at least 10% of business by next financial year, driving incremental revenue.
Growth of blends business in North America, Mexico, and Brazil is robust and expected to sustain with a targeted 25% growth in FY25.
Pricing pressure from Chinese predatory pricing is expected to ease in next 2-3 quarters as Chinese demand picks up due to government interventions, aiding margin improvement.
Fixed cost optimization, including cost reductions in European operations by Rs. 7-8 crores per quarter, should improve profitability.
Overall, despite current headwinds, business fundamentals remain solid, with focus on margin protection, cost control, and product mix optimization setting the stage for earnings growth post-market recovery.

See what Camlin Fine management said on margin guidance — free account, 30 seconds.

Fundraise plans

The transcript and associated document do not mention any current or planned fundraising activities through debt or equity. Key points: - No discussion or announcement regarding raising funds through debt or equity. - Focus is on operational aspects such as plant utilization, scaling vanillin production, managing fixed costs, and improving margins. - Management is concentrating on growing existing businesses and navigating market conditions rather than raising capital. - No references to equity issuance, debt borrowing, or fundraising plans during the Q3 FY24 earnings call or associated disclosures. In summary, Camlin Fine Sciences Limited has not indicated any current or future plans for fundraising via debt or equity as of February 9, 2024.

Order book

Current order book for Lockheed Martin includes the first battery supply order, expected to be fulfilled by end of March 2024.
Further discussions on increasing capacity for Lockheed Martin are ongoing, with more clarity expected next quarter.
Vanillin orders: substantial quantities already dispatched in Q4, with sales expected to scale up to 130-150 tons per month starting February.
Vanillin inventory held is valued roughly at Rs. 70 crores.
Customers in aroma business are cautious about entering long-term contracts due to market volatility; mainly quarterly or half-yearly contracts are favored.
The blended product business in North America, Mexico, and Brazil shows sustained growth and is expected to continue contributing positively.
European plant sales are limited currently due to shutdown but have fixed costs being reduced; revenue expected to resume post-Q4 FY24.

See what Camlin Fine management said on order book — free account, 30 seconds.

Capex plans

Yes

The company is exploring an increase in capacity for Lockheed Martin orders after fulfilling the initial supply by March 2024; more clarity expected in the next quarter.
CFS Europe plant is contemplating alternative uses, including manufacturing another HQ downstream product by a different chemistry, with a course of action to be finalized by March 2024.
The Chinese subsidiary plant remains closed but is planned to be restarted in the second half of FY25, focusing on manufacturing Heliotropin (catechol downstream).
No explicit mention of new major capex projects; emphasis is on optimizing existing capacities, reducing fixed costs, and scaling up Vanillin plant utilization progressively (expected 40-50% utilization in FY25).
The company is calibrating vanillin production based on market conditions, gradually shifting production focus (from ethyl vanillin to methyl vanillin).
Overall, focus appears on strategic capacity utilization improvements rather than large new capital investments at present.

Track Camlin Fine — get its next earnings analysis in your feed

How does Camlin Fine rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisCamlin Fine

Rev 2Mar 3

See where Camlin Fine sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Camlin Fine rank in Chemicals & Petrochemicals?

Compare Camlin Fine against every Chemicals & Petrochemicals company (Q3 FY24) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Camlin Fine's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Prasol Chemicals Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹433.6 crores . Key investor presentation takeaways from Prasol Chemicals Ltd's Q1 FY27 investor presentation — and how it rank
Vipul Organics Ltd (Q4 FY26)
Q4 FY26 (Mar 2026) total revenue: ₹5,262.37 lakhs (Consolidated) . Key concall takeaways from Vipul Organics's Q4 FY26 earnings call — and how it ranks against…
Vipul Organics Ltd (Q1 FY27)
Q1 FY27 net revenue: ₹51.78 crore, up +37.7% YoY (Page 13) . Key concall takeaways from Vipul Organics's Q1 FY27 earnings call — and how it ranks against…
Fine Organic Industries Ltd (Q1 FY27)
Revenue from Operations (Consolidated) for Q1FY27: Rs 694.2 Cr, up 18.0% YoY from Rs 588.4 Cr in Q1FY26 (Page 34). Key concall takeaways from Fine Organic…

Compare:vs Solar Industries India Ltd vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →